China Coronary Secondary Prevention Study
wash-out, one capsule after dinner for 28 days Local labs used their own intra-laboratory while other lipid lowering therapies were quality control serum to assess quality control 20 discontinued. Patients returned the bottle 28 times repeatedly before formal determination.. days later. Their physicians checked for Only labs meeting the following criteria could residual capsules and calculated compliance: participate in the study: (CV%), TC≤5%,TG≤ 35-residual capsules 5%~8%,HDL-C≤5%~8%; precision (bias%) , TC Compliance=------------------------------×100% ≤±5%,TG≤±5%~8%,HDL-C≤±10%. All Days of treatment measurement staff were trained using a uniform We again assessed serum lipid levels in patients with compliance between 80%-120% and calculated the average value (X) of the first and second results. Patients whose second lipid
levels were in the range of X±12%X were
enrolled and the second result was taken as the
baseline level. We performed a serum lipid
determination if the second level was outside of
the above range and took the average of the three
results as the baseline. We excluded patients
with isolated hypertriglyceridemia (> 4.52mmol/L).
Randomization and statistical analysis
The study was a randomized, double blind, controlled trial. We calculated the required sample size using a rate comparative single-sided test method in order to provide the study with 90% power for a single-sided α-level of 0.05, assuming a 16% accumulative rate
of primary end-point events, predicted events reduction of 20% and 5 year follow-up rate of 85% in the placebo group. We thus estimated
that a total sample of 4700 patients should be
recruited. The baseline data was monitored and
managed using Powerbuilder software. Enrollments, follow-up, termination and clinical
events were reported so that corresponding measures of quality control could be assessed.
Quality control of serum lipid measurement.
We measured serum lipids using the method recommended by the Chinese Society of Laboratory Medicine. A central laboratory, whose quality control has been conducted by American CDC since 1982, provided standard
samples. Each local lab accepted regular inter-laboratory assessments by the central lab. manual to ensure standard operating procedures[6]. Organization.
The principal investigator was responsible for all work. The study steering committee reviewed the study protocol and supervised the progress of the study; the ethical committee was responsible for protecting the interests of participants; the project executive committee handled daily study work. . The executive committee was subdivided into double-blind randomization and
data collection groups, clinical quality control, and end-point assessment group, data safety monitoring group, lipid measurement quality control group and secretary group. The execution and monitoring team, consisting of the project executive committee and secretary group, was responsible for daily work.
Results Baseline characteristics and follow-up
The research team recruited and randomized 4870 patients between November 1996 and December 2000,. The two groups were well balanced with regard to baseline characteristics,
concurrent medication and baseline lipid level (Table 2,3). The average follow-up period was
4 years with the longest period of 7 years and 2 months. 93 patients were lost to follow-up, of which 46 were in the treatment group and 47 in the control group, thus the lost to follow rate was 1.99%.
Change of Serum Lipid Levels
The baseline TC levels in the Xuezhikang and control groups were 5.36 ± 0.68 mmol/Land 5.37 ± 0.66 mmol/L respectively. Total
China Coronary Secondary Prevention Study (CCSPS) - Lipid-regulating_英语学习_外语学习_教育专区 暂无评价 0人阅读 0次下载 举报文档 China Coronary ...
Feasibility Study of W... 18页 免费 China Coronary Seconda... 暂无评价...After secondary polymer flooding, just as shown in Table 3, fractional flow...
(二)冠心病二级预防研究 1.中国冠心病二级预防研究(China Coronary Secondary Prevention Study, CCSPS)[26-27] 目前这是我国惟一一项对冠心病二级预防的大规模,前瞻...
9. 中国冠心病二级预防研究(China coronary secondary prevention study,CCSPS): 研究表明老年患者、合并糖尿病或高血压的患者治疗后获益更显著。 特殊人群的降脂临床...
我国从1996年至2000年进 行的中国冠心病二级预防研究(China Coronary Secondary Prevention Study CCSPS)是针对中国冠心病患者进行的冠心病二级预防试验, 是一项为多...
Chapter 6 Secondary synt... 暂无评价 37页 免费 Spoofing Prevention Meth... 暂无评价 18页 免费 China Coronary Secondary... 暂无评价 11页 免费...
血脂与冠心病 ——来自中国循证医学的证据解放军总医院 叶平 CCSPS 中国冠心病二级预防研究 China Coronary Secondary Prevention Study (CCSPS) --血脂康调整血脂对...
coronary heart disease.4 In the past 20 years,...“primary prevention”, “secondary prevention”, ...study in China and it showed the lowest average...
血脂康调整血脂 对冠心病二级预防的研究 China Coronary Secondary Prevention Study (CCSPS) CCSPS) 国家九五攻关课题编号:96-906-02国家九五攻关课题编号:96-906-...
中国冠心病二级预防研究 China Coronary Secondary Prevention Study 中国老年冠心病人群唯一循证医学研究(国家九五攻关课题) 课题牵头单位:阜外心血管病医院课题协作单位:...
热门文档